Loading…
Continuous Manufacturing Research Act of 2021
Legislative Progress
Introduced
June 11, 2021
Latest Action
June 11, 2021
Primary Sponsor
Abigail Davis SpanbergerDemocratic(VA)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
Continuous Manufacturing Research Act of 2021 This bill adds advanced pharmaceutical manufacturing as a research area that may be supported under the National Science Foundation's manufacturing research grant program.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2022 · fourth_quarter · Science/Technology
H.R. 869 and S. 289: Research Investment to Spark the Economy (RISE) Act of 2021 To authorize appropriations to offset costs resulting from reductions in research productivity in connection with the Coronavirus Disease 2019 (COVID-19), and for other purposes (ALL). H.R. 1160: Intelligence on Nefarious Foreign Leaders Using Education Networks for Corrupt Enrichment (INFLUENCE) Act To amend the Higher Education Act of 1965 to improve protections against foreign influence at institutions of higher education, and for other purposes (ALL). S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats and (PREVENT) Pandemics Act A bill to prepare for, and respond to, existing viruses, emerging new threats, and pandemics (provisions relating to the creation of the Advanced Research Projects Agency-Health, university centers of excellence in advanced and continuous pharmaceutical manufacturing, pandemic preparedness university centers of excellence, and research at regional biocontainment labs). H.R. 5585: Advanced Research Project Agency-Health Act To establish the Advanced Research Projects Agency-Health, and for other purposes (ALL). H.R. 6000: Cures 2.0 Act To continue the acceleration of the discovery, development, and delivery of 21st century cures, and for other purposes (provision relating to the creation of the Advanced Research Projects Agency-Health). H.R. 4369: National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2021 To amend the 21st Century Cures Act to provide for designation of institutions of higher education that provide research, data, and leadership on continuous manufacturing as National Centers of Excellence in Continuous Pharmaceutical Manufacturing, and for other purposes (ALL). S. 2589: Securing Americas Medicine Cabinet Act of 2021 A bill to amend the 21st Century Cures Act to provide for designation of institutions of higher education that provide research, data, and leadership on advanced and continuous manufacturing as National Centers of Excellence in Continuous Pharmaceutical Manufacturing, and for other purposes (ALL). H.R. 3851: Continuous Manufacturing Research Act of 2021 To improve support for research and development of advanced pharmaceutical manufacturing techniques and workforce (ALL). H.R. 5388 and S. 2740: Promoting Readiness and Ensuring Proper Active Pharmaceutical Ingredient Reserves of Essential Medicines (PREPARE) Act To establish a strategic active pharmaceutical ingredient reserve to maintain a domestic supply of active pharmaceutical ingredients and key starting materials needed for the manufacturing of essential generic medicines, and to build a pipeline for domestic active pharmaceutical ingredient production (ALL). H.R. 2617: Consolidated Appropriations Act, 2023 Making consolidated appropriations for the fiscal year ending September 30, 2023, and for providing emergency assistance for the situation in Ukraine, and for other purposes (provisions relating to university centers of excellence in advanced and continuous pharmaceutical manufacturing and the authorization of the Advanced Research Projects Agency-Health). Federal policy changes regarding fetal tissue research, biomedical research involving animals, research security, and facilities and administrative costs associated with research grants. White House and Executive Branch implementation of the CHIPS and Science Act.
Referred to the House Committee on Science, Space, and Technology.
Referred to the Subcommittee on Research and Technology.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $70,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Science/Technology
H.R. 869 and S. 289: Research Investment to Spark the Economy (RISE) Act of 2021 To authorize appropriations to offset costs resulting from reductions in research productivity in connection with the Coronavirus Disease 2019 (COVID-19), and for other purposes (ALL). H.R. 1160: Intelligence on Nefarious Foreign Leaders Using Education Networks for Corrupt Enrichment (INFLUENCE) Act To amend the Higher Education Act of 1965 to improve protections against foreign influence at institutions of higher education, and for other purposes (ALL). S. 1260: United States Innovation and Competition Act of 2021 A bill to establish a new Directorate for Technology and Innovation in the National Science Foundation, to establish a regional technology hub program, to require a strategy and report on economic security, science, research, innovation, manufacturing, and job creation, to establish a critical supply chain resiliency program, and for other purposes (provisions relating to funding for the National Science Foundation, NASA, and the Departments of Commerce and Energy; provisions on research and development and foreign gift/contract reporting at U.S. institutions of higher education). H.R. 4521: America Creating Opportunities for Manufacturing, Pre-Eminence in Technology, and Economic Strength (COMPETES) Act of 2022 Vehicle for the Houses comprehensive innovation and competitiveness legislation (provisions relating to funding for the National Science Foundation, NASA, and the Departments of Commerce and Energy; provisions on research and development and foreign gift/contract reporting at U.S. institutions of higher education; immigration provisions relating to advanced degree holders from U.S. institutions of higher education; and provision relating to university centers of excellence in advanced and continuous pharmaceutical manufacturing). H.R. 4346: CHIPS and Science Act Vehicle for bipartisan legislation to support domestic semiconductor research and development and reauthorize major science agencies (provisions relating to funding for the National Science Foundation, NASA, and the Departments of Commerce and Energy; provisions on research and development and foreign gift/contract reporting at U.S. institutions of higher education). S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats and (PREVENT) Pandemics Act A bill to prepare for, and respond to, existing viruses, emerging new threats, and pandemics (provisions relating to the creation of the Advanced Research Projects Agency-Health, university centers of excellence in advanced and continuous pharmaceutical manufacturing, pandemic preparedness university centers of excellence, and research at regional biocontainment labs). H.R. 5585: Advanced Research Project Agency-Health Act To establish the Advanced Research Projects Agency-Health, and for other purposes (ALL). H.R. 6000: Cures 2.0 Act To continue the acceleration of the discovery, development, and delivery of 21st century cures, and for other purposes (provision relating to the creation of the Advanced Research Projects Agency-Health). H.R. 2225: National Science Foundation for the Future Act To authorize appropriations for fiscal years 2022, 2023, 2024, 2025, and 2026 for the National Science Foundation, and for other purposes (ALL). H.R. 3593: Department of Energy Science for the Future Act To provide guidance for and investment in the research and development activities of the Department of Energy Office of Science, and for other purposes (ALL). H.R. 4369: National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2021 To amend the 21st Century Cures Act to provide for designation of institutions of higher education that provide research, data, and leadership on continuous manufacturing as National Centers of Excellence in Continuous Pharmaceutical Manufacturing, and for other purposes (ALL). S. 2589: Securing Americas Medicine Cabinet Act of 2021 A bill to amend the 21st Century Cures Act to provide for designation of institutions of higher education that provide research, data, and leadership on advanced and continuous manufacturing as National Centers of Excellence in Continuous Pharmaceutical Manufacturing, and for other purposes (ALL). H.R. 3851: Continuous Manufacturing Research Act of 2021 To improve support for research and development of advanced pharmaceutical manufacturing techniques and workforce (ALL). H.R. 5388 and S. 2740: Promoting Readiness and Ensuring Proper Active Pharmaceutical Ingredient Reserves of Essential Medicines (PREPARE) Act To establish a strategic active pharmaceutical ingredient reserve to maintain a domestic supply of active pharmaceutical ingredients and key starting materials needed for the manufacturing of essential generic medicines, and to build a pipeline for domestic active pharmaceutical ingredient production (ALL). S. 4900 SBIR and STTR Extension Act of 2022 A bill to reauthorize the SBIR and STTR programs and pilot programs, and for other purposes (ALL). Federal policy changes regarding fetal tissue research, biomedical research involving animals, research security, and facilities and administrative costs associated with research grants. Pending federal legislation to enhance university climate research, service, and resiliency.
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Science/Technology
H.R. 869 and S. 289: Research Investment to Spark the Economy (RISE) Act of 2021 To authorize appropriations to offset costs resulting from reductions in research productivity in connection with the Coronavirus Disease 2019 (COVID-19), and for other purposes (ALL). H.R. 1160: Intelligence on Nefarious Foreign Leaders Using Education Networks for Corrupt Enrichment (INFLUENCE) Act To amend the Higher Education Act of 1965 to improve protections against foreign influence at institutions of higher education, and for other purposes (ALL). S. 1260: United States Innovation and Competition Act of 2021 A bill to establish a new Directorate for Technology and Innovation in the National Science Foundation, to establish a regional technology hub program, to require a strategy and report on economic security, science, research, innovation, manufacturing, and job creation, to establish a critical supply chain resiliency program, and for other purposes (provisions relating to funding for the National Science Foundation, NASA, and the Departments of Commerce and Energy; provisions on research and development and foreign gift/contract reporting at U.S. institutions of higher education). H.R. 4521: America Creating Opportunities for Manufacturing, Pre-Eminence in Technology, and Economic Strength (COMPETES) Act of 2022 Vehicle for the Houses comprehensive innovation and competitiveness legislation (provisions relating to funding for the National Science Foundation, NASA, and the Departments of Commerce and Energy; provisions on research and development and foreign gift/contract reporting at U.S. institutions of higher education; immigration provisions relating to advanced degree holders from U.S. institutions of higher education; and provision relating to university centers of excellence in advanced and continuous pharmaceutical manufacturing). S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats and (PREVENT) Pandemics Act A bill to prepare for, and respond to, existing viruses, emerging new threats, and pandemics (provisions relating to the creation of the Advanced Research Projects Agency-Health, university centers of excellence in advanced and continuous pharmaceutical manufacturing, pandemic preparedness university centers of excellence, and research at regional biocontainment labs). H.R. 5585: Advanced Research Project Agency-Health Act To establish the Advanced Research Projects Agency-Health, and for other purposes (ALL). H.R. 6000: Cures 2.0 Act To continue the acceleration of the discovery, development, and delivery of 21st century cures, and for other purposes (provision relating to the creation of the Advanced Research Projects Agency-Health). H.R. 2225: National Science Foundation for the Future Act To authorize appropriations for fiscal years 2022, 2023, 2024, 2025, and 2026 for the National Science Foundation, and for other purposes (ALL). H.R. 3593: Department of Energy Science for the Future Act To provide guidance for and investment in the research and development activities of the Department of Energy Office of Science, and for other purposes (ALL). H.R. 4369: National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2021 To amend the 21st Century Cures Act to provide for designation of institutions of higher education that provide research, data, and leadership on continuous manufacturing as National Centers of Excellence in Continuous Pharmaceutical Manufacturing, and for other purposes (ALL). S. 2589: Securing Americas Medicine Cabinet Act of 2021 A bill to amend the 21st Century Cures Act to provide for designation of institutions of higher education that provide research, data, and leadership on advanced and continuous manufacturing as National Centers of Excellence in Continuous Pharmaceutical Manufacturing, and for other purposes (ALL). H.R. 3851: Continuous Manufacturing Research Act of 2021 To improve support for research and development of advanced pharmaceutical manufacturing techniques and workforce (ALL). H.R. 5388 and S. 2740: Promoting Readiness and Ensuring Proper Active Pharmaceutical Ingredient Reserves of Essential Medicines (PREPARE) Act To establish a strategic active pharmaceutical ingredient reserve to maintain a domestic supply of active pharmaceutical ingredients and key starting materials needed for the manufacturing of essential generic medicines, and to build a pipeline for domestic active pharmaceutical ingredient production (ALL). Federal policy changes regarding fetal tissue research, biomedical research involving animals, research security, and facilities and administrative costs associated with research grants. Pending federal legislation to enhance university climate research, service, and resiliency.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Science/Technology
H.R. 869 and S. 289: Research Investment to Spark the Economy (RISE) Act of 2021 To authorize appropriations to offset costs resulting from reductions in research productivity in connection with the Coronavirus Disease 2019 (COVID-19), and for other purposes (ALL). H.R. 1160: Intelligence on Nefarious Foreign Leaders Using Education Networks for Corrupt Enrichment (INFLUENCE) Act To amend the Higher Education Act of 1965 to improve protections against foreign influence at institutions of higher education, and for other purposes (ALL). S. 1260 and H.R. 2731: United States Innovation and Competition Act of 2021 A bill to establish a new Directorate for Technology and Innovation in the National Science Foundation, to establish a regional technology hub program, to require a strategy and report on economic security, science, research, innovation, manufacturing, and job creation, to establish a critical supply chain resiliency program, and for other purposes (provisions relating to funding for the National Science Foundation, NASA, and the Departments of Commerce and Energy; provisions on research and development and foreign gift/contract reporting at U.S. institutions of higher education). H.R. 4521: America Creating Opportunities for Manufacturing, Pre-Eminence in Technology, and Economic Strength (COMPETES) Act of 2022 Vehicle for the Houses comprehensive innovation and competitiveness legislation (provisions relating to funding for the National Science Foundation, NASA, and the Departments of Commerce and Energy; provisions on research and development and foreign gift/contract reporting at U.S. institutions of higher education; immigration provisions relating to advanced degree holders from U.S. institutions of higher education; and provision relating to advanced and continuous pharmaceutical manufacturing university centers of excellence). S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats and (PREVENT) Pandemics Act A bill to prepare for, and respond to, existing viruses, emerging new threats, and pandemics (provisions relating to the creation of the Advanced Research Projects Agency-Health, advanced and continuous pharmaceutical manufacturing university centers of excellence, pandemic preparedness university centers of excellence, and research at regional biocontainment labs). H.R. 5585: Advanced Research Project Agency-Health Act To establish the Advanced Research Projects Agency-Health, and for other purposes (ALL). H.R. 6000: Cures 2.0 Act To continue the acceleration of the discovery, development, and delivery of 21st century cures, and for other purposes (provision relating to the creation of the Advanced Research Projects Agency-Health). H.R. 2225: National Science Foundation for the Future Act To authorize appropriations for fiscal years 2022, 2023, 2024, 2025, and 2026 for the National Science Foundation, and for other purposes (ALL). H.R. 3593: Department of Energy Science for the Future Act To provide guidance for and investment in the research and development activities of the Department of Energy Office of Science, and for other purposes (ALL). H.R. 4369: National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2021 To amend the 21st Century Cures Act to provide for designation of institutions of higher education that provide research, data, and leadership on continuous manufacturing as National Centers of Excellence in Continuous Pharmaceutical Manufacturing, and for other purposes (ALL). S. 2589: Securing Americas Medicine Cabinet Act of 2021 A bill to amend the 21st Century Cures Act to provide for designation of institutions of higher education that provide research, data, and leadership on advanced and continuous manufacturing as National Centers of Excellence in Continuous Pharmaceutical Manufacturing, and for other purposes (ALL). H.R. 3851: Continuous Manufacturing Research Act of 2021 To improve support for research and development of advanced pharmaceutical manufacturing techniques and workforce (ALL). H.R. 5388 and S. 2740: Promoting Readiness and Ensuring Proper Active Pharmaceutical Ingredient Reserves of Essential Medicines (PREPARE) Act To establish a strategic active pharmaceutical ingredient reserve to maintain a domestic supply of active pharmaceutical ingredients and key starting materials needed for the manufacturing of essential generic medicines, and to build a pipeline for domestic active pharmaceutical ingredient production (ALL). Federal policy changes regarding fetal tissue research and research security.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Science/Technology
H.R. 869 and S. 289: Research Investment to Spark the Economy (RISE) Act of 2021 To authorize appropriations to offset costs resulting from reductions in research productivity in connection with the Coronavirus Disease 2019 (COVID-19), and for other purposes (ALL). H.R. 1160: Intelligence on Nefarious Foreign Leaders Using Education Networks for Corrupt Enrichment (INFLUENCE) Act To amend the Higher Education Act of 1965 to improve protections against foreign influence at institutions of higher education, and for other purposes (ALL). S. 1260 and H.R. 2731: United States Innovation and Competition Act of 2021 A bill to establish a new Directorate for Technology and Innovation in the National Science Foundation, to establish a regional technology hub program, to require a strategy and report on economic security, science, research, innovation, manufacturing, and job creation, to establish a critical supply chain resiliency program, and for other purposes (provisions relating to funding for the National Science Foundation, NASA, and the Departments of Commerce and Energy; provisions on research and development and foreign gift/contract reporting at U.S. institutions of higher education). H.R. 2225: National Science Foundation for the Future Act To authorize appropriations for fiscal years 2022, 2023, 2024, 2025, and 2026 for the National Science Foundation, and for other purposes (ALL). H.R. 3593: Department of Energy Science for the Future Act To provide guidance for and investment in the research and development activities of the Department of Energy Office of Science, and for other purposes (ALL). H.R. 4369: National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2021 To amend the 21st Century Cures Act to provide for designation of institutions of higher education that provide research, data, and leadership on continuous manufacturing as National Centers of Excellence in Continuous Pharmaceutical Manufacturing, and for other purposes (ALL). S. 2589: Securing Americas Medicine Cabinet Act of 2021 A bill to amend the 21st Century Cures Act to provide for designation of institutions of higher education that provide research, data, and leadership on advanced and continuous manufacturing as National Centers of Excellence in Continuous Pharmaceutical Manufacturing, and for other purposes (ALL). H.R. 3851: Continuous Manufacturing Research Act of 2021 To improve support for research and development of advanced pharmaceutical manufacturing techniques and workforce (ALL). H.R. 5585: Advanced Research Project Agency-Health Act To establish the Advanced Research Projects Agency-Health, and for other purposes (ALL). H.R. 6000: Cures 2.0 Act To continue the acceleration of the discovery, development, and delivery of 21st century cures, and for other purposes (provision relating to the creation of the Advanced Research Projects Agency-Health). Federal policy changes regarding fetal tissue research and research security.
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Trade (domestic/foreign)
H.R. 2653: MMEDS Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 2731: Endless Frontier Act - Provisions related to medical supply chains and domestic manufacturing H.R. 2870: Essential Medicines Strategic Stockpile Act of 2021 - Provisions related to medical supply chains and strategic stockpiles H.R. 3035: Preventing Foreign Attempts to Erode Healthcare Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3236: AMIGOS Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3683: Securing Americas Pharmaceutical Supply Chain Act - Provisions related to medical supply chains H.R. 3694: To direct the Secretary of Health and Human Services, in consultation with the United States Trade Representative and other heads of Federal agencies, to submit to Congress a report the impact of a waiver of certain obligations of member nations under the Agreement on Trade-Related Aspects of Intellectual Property Rights on global COVID-19 vaccine access, and for other purposes. - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3788: Protecting American Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3811: TRIPP Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3851: Continuous Manufacturing Research Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 3927: MADE in America Act - Provisions related to medical supply chains and domestic manufacturing H.R. 4121, PRO Seniors Act, provisions related to drug rebates H.R. 4369: National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 4376: USTRx Act - Provisions related to international trade policy and manufacturing S. 298: Pharmacy Benefit Manager Accountability Study Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency S. 1176: Onshoring Essential Antibiotics Act - Provisions related to medical supply chains S. 1203: MMEDS Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 1260: United States Innovation and Competition Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 1366: Pharmaceutical Supply Chain Defense and Enhancement Act - Provisions related to medical supply chains and domestic manufacturing S. 1367: United States Pharmaceutical Supply Chain Review Act - Provisions related to medical supply chains and domestic manufacturing S. 1388: Prescription Pricing for the People Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency S. 1683: Preventing Foreign Attempts to Erode Healthcare Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property S. 2495: Protecting our Pharmaceutical Supply Chain from China Act of 2021 - Provisions related to medical supply chains Trade Agreements including USMCA and related policy issues Biopharmaceutical innovation policy issues nternational intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver
2021 · third_quarter · Trade (domestic/foreign)
H.R. 1186: Supply Chain Security and Pharmaceutical Authentication Act of 2021 - Provisions related to medical supply chains H.R. 2653: MMEDS Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 2731: Endless Frontier Act - Provisions related to medical supply chains and domestic manufacturing H.R. 2870: Essential Medicines Strategic Stockpile Act of 2021 - Provisions related to medical supply chains and strategic stockpiles H.R. 3035: Preventing Foreign Attempts to Erode Healthcare Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3236: AMIGOS Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3682: Improving Transparency to Lower Drug Costs Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency H.R. 3683: Securing Americas Pharmaceutical Supply Chain Act - Provisions related to medical supply chains H.R. 3694: To direct the Secretary of Health and Human Services, in consultation with the United States Trade Representative and other heads of Federal agencies, to submit to Congress a report the impact of a waiver of certain obligations of member nations under the Agreement on Trade-Related Aspects of Intellectual Property Rights on global COVID-19 vaccine access, and for other purposes - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3788: Protecting American Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3811: TRIPP Act - Provisions related to WTO TRIPS patent waivers and intellectual property H.R. 3851: Continuous Manufacturing Research Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 3927: MADE in America Act - Provisions related to medical supply chains and domestic manufacturing H.R. 4295: Supply Chain Vulnerability Assessment Act of 2021 - Provisions related to medical supply chains H.R. 4369: National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2021 - Provisions related to medical supply chains and domestic manufacturing H.R. 4376: USTRx Act - Provisions related to international trade policy and manufacturing S. 298: Pharmacy Benefit Manager Accountability Study Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency S. 1176: Onshoring Essential Antibiotics Act - Provisions related to medical supply chains S. 1203: MMEDS Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 1260: United States Innovation and Competition Act of 2021 - Provisions related to medical supply chains and domestic manufacturing S. 1366: Pharmaceutical Supply Chain Defense and Enhancement Act - Provisions related to medical supply chains and domestic manufacturing S. 1367: United States Pharmaceutical Supply Chain Review Act - Provisions related to medical supply chains and domestic manufacturing S. 1388: Prescription Pricing for the People Act of 2021 - Provisions related to medical supply chains and prescription drug pricing transparency S. 1683: Preventing Foreign Attempts to Erode Healthcare Innovation Act - Provisions related to WTO TRIPS patent waivers and intellectual property S. 2495: Protecting our Pharmaceutical Supply Chain from China Act of 2021 - Provisions related to medical supply chains Trade Agreements including USMCA and related policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver
| Democratic |
| NY |
| Peter Meijer | Republican | MI |
Client expense: $1,200,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
Client expense: $7,440,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE